Docket No.: DAVI271.001APC

INFORMATION DISCLOSURE STATEMENT

Applicant

Ralph, Stephen John

App. No

10/575,813

Filed

April 14, 2006

For

IMMUNOMODULATING

COMPOSITIONS AND USES

THEREFOR

Examiner

Unknown

Art Unit

1645

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 8 references to be considered by the Examiner. Also enclosed are 8 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: January 16, 2007

By:

Raymond D. Smith

Registration No. 55,634

Agent of Record Customer No. 20,995

(805) 547-5580

3311954 011607

| | Application No. | 10/575,813 |
|---------------------------------------|----------------------|---------------------|
| INFORMATION DISCLOSURE | Filing Date | April 14, 2006 |
| STATEMENT BY APPLICANT | First Named Inventor | Ralph, Stephen John |
| OTATEMENT BY ALLEGANT | Art Unit | 1645 |
| (Multiple sheets used when necessary) | Examiner | Unknown |
| SHEET 1 OF 1 | Attorney Docket No. | DAVI271.001APC |

| | U.S. PATENT DOCUMENTS | | | | |
|----------------------|-----------------------|---|--------------------------------|-------------------------------|--|
| Examiner Initials | Cite No. | Document Number Number - Kind Code (if known) Example: 1,234,567 B1 | Publication Date MM-DD-YYYY | Name of Patentee or Applicant | Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear |
| | | | | | |

| | FOREIGN PATENT DOCUMENTS | | | | | | |
|----------------------|--------------------------|--|-----------------------------|---|--|----------------|--|
| Examiner Initials | Cite No. | Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1 | Publication Date MM-DD-YYYY | Name of Patentee or Applicant | Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear | T ¹ | |
| | 1 | WO 00/63251 A1 | 10-26-2000 | KATHOLIEKE UNIVERSITEIT NIJMEGEN | | | |
| | 2 | WO 02/50119 A2 | 06-27-2002 | STICHTING KATHOLIEKE UNIVERSITEIT | | | |
| | 3 | WO 2004/041292 A2 | 05-21-2004 | VERENIGING VOOR CHRISTELIJK WETEN- SCHAPPELIJK ONDERWIJS | | | |

| | | NON PATENT LITERATURE DOCUMENTS | |
|----------------------|-------------|--|--|
| Examiner Initials | Cite No. | itom (book magazina jaurnal parial aumoosium satalag ata) data paga(a) yaluma jagus 📗 📗 | |
| | 4 | International Search Report for International application No. PCT/AU2004/001429. | |
| | 5 | FUKUMORI, T. et al. 2003 "CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis" Cancer Research 63:8302-8311. | |
| | 6 | LANTÉRI, M. et al. 2003 "Altered T cell surface glycosylation in HIV-1 infection results in increased susceptibility to galectin-1-induced cell death" <i>Glycobiology</i> 13 :909-918. | |
| | 7 | PERILLO, N.L. et al. 1995 "Apoptosis of T cells mediated by galectin-1" Nature 378:736-739. | |
| | 8 | RABINOVICH, G.A. et al. 2002 "Unlocking the secrets of galectins: a challenge at the frontier of glyco-immunology" <i>J Leukocyte Biology</i> 71 :741-752. | |

3311740 011607

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.